| Literature DB >> 36227364 |
Gisela H Degen1, Jan G Hengstler2, Ahmed Ghallab3,4, Reham Hassan5,6, Daniela González5, Zaynab Hobloss5, Lisa Brackhagen5, Maiju Myllys5, Adrian Friebel7, Abdel-Latif Seddek6, Rosemarie Marchan5, Benedikt Cramer8, Hans-Ulrich Humpf8, Stefan Hoehme7.
Abstract
The mycotoxin ochratoxin A (OTA) is a contaminant in food that causes nephrotoxicity and to a minor degree hepatotoxicity. Recently, we observed that OTA induces liver damage preferentially to the cytochrome P450 (CYP)-expressing pericentral lobular zone, similar to hepatotoxic substances known to be metabolically toxified by CYP, such as acetaminophen or carbon tetrachloride. To investigate whether CYP influences OTA toxicity, we used a single dose of OTA (7.5 mg/kg; intravenous) with and without pre-treatment with the pan CYP-inhibitor 1-aminobenzotriazole (ABT) 2 h before OTA administration. Blood, urine, as well as liver and kidney tissue samples were collected 24 h after OTA administration for biochemical and histopathological analyses. Inhibition of CYPs by ABT strongly increased the nephro- and hepatotoxicity of OTA. The urinary kidney damage biomarkers kidney injury molecule-1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) were increased > 126-fold and > 20-fold, respectively, in mice treated with ABT and OTA compared to those receiving OTA alone. The blood biomarkers of liver damage, alanine transaminase (ALT) and aspartate transaminase (AST) both increased > 21- and 30-fold, respectively, when OTA was administered to ABT pre-treated mice compared to the effect of OTA alone. Histological analysis of the liver revealed a pericentral lobular damage induced by OTA despite CYP-inhibition by ABT. Administration of ABT alone caused no hepato- or nephrotoxicity. Overall, the results presented are compatible with a scenario where CYPs mediate the detoxification of OTA, yet the mechanisms responsible for the pericental liver damage pattern still remain to be elucidated.Entities:
Keywords: Bioactivation; Detoxification; Drug metabolism; Metabolic zonation; Mycotoxins
Mesh:
Substances:
Year: 2022 PMID: 36227364 PMCID: PMC9584869 DOI: 10.1007/s00204-022-03395-y
Source DB: PubMed Journal: Arch Toxicol ISSN: 0340-5761 Impact factor: 6.168